# Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma

> **NCT03382886** · PHASE1 · TERMINATED · sponsor: **University of Utah** · enrollment: 1 (actual)

## Conditions studied

- Hepatocellular Carcinoma

## Interventions

- **DRUG:** Nivolumab
- **DRUG:** Bevacizumab

## Key facts

- **NCT ID:** NCT03382886
- **Lead sponsor:** University of Utah
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2018-04-11
- **Primary completion:** 2018-07-26
- **Final completion:** 2019-07-02
- **Target enrollment:** 1 (ACTUAL)
- **Why stopped:** PI decided to terminate due to low/slow accrual
- **Last updated:** 2019-12-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03382886

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03382886, "Nivolumab and Bevacizumab in Patients With Advanced and or Metastatic Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03382886. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*